Skip to content

Harnessing exhaled breath for lung cancer early detection

Harnessing exhaled hydrogen peroxide for early lung cancer detection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN81020233
Enrollment
40
Registered
2024-05-21
Start date
2024-04-01
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer

Interventions

This is a pilot study assessing whether Inflammacheck can distinguish patients with lung cancer from non-cancer controls. Participants will be identified from outpatient clinics and lung health checks

Sponsors

Northern Care Alliance NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 110 Years

Inclusion criteria

Inclusion criteria: Cases: 1. Confirmed diagnosis of lung cancer or highly suggestive radiological findings 2. Aged 18 years or older Controls: 1. Aged 18 years or over 2. More than 20 pack year history of smoking 3. CT scan negative for lung cancer within the last 2 years

Exclusion criteria

Exclusion criteria: 1. Concurrent active non-lung malignancy 2. Curative treatment for a non-lung malignancy less than 2 years previously 3. Treatment for lung cancer 4. Acute infection 5. No capacity to consent

Design outcomes

Primary

MeasureTime frame
Exhaled hydrogen peroxide is measured using the Inflammacheck at the time of recruitment

Secondary

MeasureTime frame
Exhaled breath condensate collected at recruitment will be analysed by mass spectrometry

Countries

England, United Kingdom

Contacts

Public ContactSean Knight
sean.knight@nca.nhs.uk+44 (0)7817775283

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 23, 2026